Author: Customer Service

Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1 months vs 7.2 months; log-rank p=0.01) in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving elraglusib/GnP Risk of death was reduced by 37% (HR=0.63) in patients treated with elraglusib/GnP Data featured as an oral presentation at the ASCO Annual Meeting Company plans to engage with FDA in the second half of 2025 to align on a path towards product registration Company to host KOL event today at 6:30 pm CDT to discuss 1801 Part 3B resultsCHICAGO and FORT WORTH, Texas, May 31, 2025 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutation Vepdegestrant was generally well tolerated, with few discontinuations and low rates of gastrointestinal-related adverse events Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer Data to be featured in a late-breaking oral presentation at ASCO and simultaneously published in the New England Journal of Medicine Arvinas will host a conference call to discuss these results on Monday, June 2, at 8:00 a.m. ETNEW HAVEN, Conn. and NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) — Arvinas, Inc....

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and fulvestrant alone1 The PIK3CA mutation is found in approximately 40% of HR-positive advanced breast cancers and is associated with a poor prognosis2,3 New data are being presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the New England Journal of Medicine1Basel, 31 May 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive final results from the overall survival (OS) analysis of the phase III INAVO120 study. These data showed ItovebiTM (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, reduced the risk of death by more than 30% compared...

Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p

26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastases Deep and durable responses ongoing for up to 37 weeks through the data cutoff, accompanied by substantial decreases in tumor biomarkers and improvements in clinical symptoms MSS CRC patient with liver metastasis and previously reported confirmed partial response from Phase 1C (combination dose escalation) remains on treatment after more than 14 months Combination continued to demonstrate differentiated safety and tolerability profile with low incidence of colitis and other immune-related adverse events Data are being presented in a poster presentation today at the 2025 ASCO Annual Meeting WALTHAM, Mass., May 31, 2025 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc....

WithSecure Corporation, Stock Exchange Release, 31 May 2025 at 9:45 EEST WithSecure has completed the transaction of Cyber security consulting divestment to Neqst WithSecure announced on 23 January 2025 its intention to divest the cyber security consulting business to Neqst, Swedish investment company. On 31 May 2025, the parties completed the transaction in accordance with the sale and purchase agreement. EUR 13.5 million, corresponding to 60 % of the agreed enterprise value of EUR 22.5 million, deducted by the transferring net assets of the business, is paid in cash by the buyer. The remaining 40 % is variable purchase price, based on the performance of the business in 2025 and 2026, and it becomes payable in two installments in the beginning of 2026 and 2027. All closing conditions of the transaction have been fulfilled. With the...

Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation daily oral options Latest Phase 3 SOLARIS data show no suspected or confirmed PDSS events with TEV-‘749 after more than 3,400 subcutaneous injections in study participants to date As a leader in neuroscience, Teva is committed to researching and developing long-acting treatment options that help address unmet needs for individuals living with schizophreniaPARSIPPANY, N.J. and TEL AVIV, Israel, May 30, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of real-world clinical outcomes, treatment patterns and healthcare...

More than half of residents with tardive dyskinesia (TD) residing in long-term care (LTC) settings do not receive standard of care treatment, and one-quarter are left untreated LTC residents are often given a broader diagnosis of extrapyramidal syndrome, which can lead to incorrect treatment options for TD Teva is committed to continuing to advance research to better understand and help address unmet needs among patients living with TD in LTC settings as well as other settingsPARSIPPANY, N.J. and TEL AVIV, Israel, May 30, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a study of treatment patterns among patients with tardive dyskinesia (TD) residing in long-term care (LTC) facilities, highlighting a critical gap in TD...

– NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES – VANCOUVER, BC, May 30, 2025 (GLOBE NEWSWIRE) — New Wave Holdings Corp. (the “Company” or “New Wave”) (CSE: NWAI, FWB: 0XM0, OTCPK: TRMNF) announces, further to its news release of May 20 and May 29, 2025, that the Company has closed the previously announced non-brokered private placement under the Listed Issuer Financing Exemption (as defined herein) of 7,000,000 units of the Company (the “Units”) at $0.055 per Unit for gross proceeds of $385,000 (the “LIFE Offering”). Each Unit consists of one common share in the capital of the Company (a “Share”) and one transferrable common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to purchase one additional Share on or after August 13, 2025 at a price of $0.07 on or...